De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Abroad (travel likely)RecruitingPHASE2

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma · Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Study coordinator (Shelby Watkin) · 480-342-2000
Contact: Principal Investigator (Samir H. Patel, M.D.)
Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Study coordinator (Caroline Pamboukas) · 904-953-2791
Contact: Principal Investigator (Adam L. Holtzman, M.D.)
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (David M. Routman, M.D.)

Study leads

David M, Routman, M.D.
Principal Investigator
Mayo Clinic in Rochester

View source on ClinicalTrials.gov Contact study team (email)